2μg (R: reducing condition, N:non-reducing condition).
Product Details
Product Details
Product Specification
| Species | Human |
| Synonyms | ALRH, BHR1, MGC116786, MGC116788, P600, Interleukin-13 |
| Accession | AAK53823.1 |
| Amino Acid Sequence | Gly21-Asn132 with His Tag at the C-Terminus |
| Expression System | HEK293 |
| Molecular Weight | 25-40kDa (Reducing) |
| Purity | >90% by SDS-PAGE & HPLC |
| Conjugation | Unconjugated |
| Tag | His Tag |
| Physical Appearance | Lyophilized powder |
| Storage Buffer | PBS, PH7.4, 5% trehalose |
| Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
| Stability & Storage | · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. |
| Reference | 1.Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, Katelaris C, Tohda Y, Zhang B, Staudinger H, Pirozzi G, Amin N, Ruddy M, Akinlade B, Khan A, Chao J, Martincova R, Graham NMH, Hamilton JD, Swanson BN, Stahl N, Yancopoulos GD, Teper A. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018 Jun 28;378(26):2486-2496. |
Background
IL-13 (interleukin 13) is a type I cytokine secreted by activated Th2 cells, mast cells, and basophils, belonging to the four-helix bundle cytokine family. Its protein structure consists of four α-helices (A, B, C, D) stabilized by two disulfide bonds forming a compact globular conformation, and recombinant expression with His-tag technology facilitates purification and structural studies. This cytokine activates the JAK1/TYK2-STAT6 signaling pathway through type I receptors (IL-13Rα1/IL-4Rα heterodimer), regulating B cell IgE class switching, mucus production, and eosinophil chemotaxis; concurrently, binding to IL-13Rα2 (decoy receptor) participates in inflammatory modulation and tissue fibrosis. In clinical medicine, IL-13 serves as a core driver of type 2 inflammatory diseases, with biologics targeting the IL-4/IL-13 pathway such as dupilumab approved for treating moderate-to-severe asthma, atopic dermatitis, and chronic rhinosinusitis with nasal polyps. Furthermore, IL-13 receptor α2 is highly expressed in solid tumors including glioblastoma, emerging as a novel tumor target for CAR-T cells and bispecific antibodies, demonstrating broad clinical application prospects spanning from inflammatory regulation to cancer immunotherapy.
Picture
Picture
SDS-PAGE
SEC-HPLC
The purity of IL-13 His Tag Protein, Human is more than 90% determined by SEC-HPLC.
ELISA
Immobilized IL-13 His Tag Protein, Human (Cat. No. UA016041) at 1.0μg/mL (100μL/well) can bind Biotinylated Human IL-13Ra2 Protein with EC50 of 8.76-10.08 ng/mL.
